Transformation of the Russian pharmaceutical market under sanctions (2022-2025): Shift to import substitution and new partnerships
نویسندگان
doi
10.48309/jmpcr.2026.570449.1970چکیده
This study provides a comprehensive analysis of the transformation of the Russian pharmaceutical market from 2022 to 2025 under the influence of international sanctions. Drawing on data from leading industry agencies (DSM Group, RNC Pharma), official statistics, and the State Register of Medicines, the research examines key trends and structural changes following major disruptions in external economic relations. The findings show a moderate reduction in the share of imported finished medicinal products in monetary terms — from approximately 60–65% in 2021 to around 52–55% in 2024, with forecasts suggesting a further gradual decline toward 45–50% by 2025. This shift has been accompanied by an increase in the share of domestically produced and localized products. Import substitution has progressed most successfully in the mass generic segment, particularly for cardiovascular diseases and diabetes, where Russian manufacturers such as Pharmstandard, Geropharm, and R-Pharm have strengthened their positions. However, significant challenges persist in ensuring patient access to innovative medicines for oncology, autoimmune diseases, and rare (orphan) conditions, where full replacement of original biologics has not been achieved. A major reorientation of supply chains has occurred, with the share of active pharmaceutical ingredients (APIs) imported from China increasing substantially (estimated at 55–70% depending on the reporting period and methodology), while dependence on European suppliers has sharply declined. Overall, the market demonstrates partial resilience in the basic generic segment, but remains vulnerable due to continued heavy reliance on imported APIs and limited access to innovative therapies .